

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER ACTION	see Form PCT/ISA/220 as well as, where applicable, item 5 below.
18202 - 028WO1 International application No.	International filing date (day/month/yea	(Earliest) Priority Date (day/month/year)
PCT/US2005/007867	11/03/2005	12/03/2004
Applicant		
LIGAND PHARMACEUTICALS INC	CORPORATED	
This International Search Report has bee according to Article 18. A copy is being tra	n prepared by this International Searchir ansmitted to the International Bureau.	g Authority and is transmitted to the applicant
This International Search Report consists		•
It is also accompanied by	a copy of each prior art document cited	in this report.
language in which it was filed, un	less otherwise indicated under this item. search was carried out on the basis of a	he basis of the international application in the translation of the international application furnished to
b. With regard to any nucle	otide and/or amino acid sequence dis	closed in the international application, see Box No. I.
2. Certain claims were fou	and unsearchable (See Box II).	
3. Unity of invention is lac	king (see Box III).	
4. With regard to the title,		
	ubmitted by the applicant.	
the text has been establis	shed by this Authority to read as follows:	
·	·	
*		
5. With regard to the abstract,		
	ubmitted by the applicant.	
X the text has been establis	shed, according to Rule 38.2(b), by this	Authority as it appears in Box No. IV. The applicant al search report, submit comments to this Authority.
6. With regard to the drawings,		
	published with the abstract is Figure No.	
as suggested by	•	·
	is Authority, because the applicant faile	
	is Authority, because this figure better o	haracterizes the invention.
b. none of the figures is to b	e published with the abstract.	





INTERNATIONAL SEARCH REPORT International application No. PCT/US2005/007867

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1,3-25,28,29,46-51 (all partially),61 (completely),58 62-82 (all partially)
Remark on Protest The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1,3-25,28,29,46-51 (all partially), 61 (completely), 58,62-82 (all partially)

Compounds of general formula (I) according to claim 1 as well as their pharmaceutical use and compositions according to claims 63-82

2. claims: 1-25 (all partially), 26 and 27 (completely), 28 and 29 (partially), 30-38 (all completely), 46-51,58-82 (all partially)

Compounds of general formula (II) according to claim 1 as well as their pharmaceutical use and compositions according to claims 63-82

3. claims: 1,3-25,28,29,46-51,58 (all partially), 59 and 60 (completely), 62-82 (all partially)

Compounds of general formula (III) according to claim 1 as well as their pharmaceutical use and compositions according to claims 63-82

4. claims: 1-25,28,29 (all partially), 39-41 (completely), 46-58,62-82 (all partially)

Compounds of general formula (IV) according to claim 1 as well as their pharmaceutical use and compositions according to claims 63-82

5. claims: 1,3-25,28,29,42 (all partially), 43-45 (completely), 46-51,58,62-82 (all partially)

Compounds of general formula (V) according to claim 1 as well as their pharmaceutical use and compositions according to claims 63-82

6. claims: 1,3-25,28,29,42,46-51 (all partially), 52-57 (completely), 58,62-82 (all partially)

Compounds of general formula (VI) according to claim 1 as well as their pharmaceutical use and compositions according to claims 63-82

Provided herein are compounds

having a structure

selected from among Formula I, Formula II, Formula III, Formula IV, Formula V and Formula VI:

$$R^{3a}$$
 R^{6}
 R^{7}
 R^{8}
 R^{9}
 R^{1}
 R^{5}
 R^{4}
 R^{11}

(I)

(II)

$$\begin{array}{c|ccccc}
R^{19} & R^{20} & R^{22} \\
R^{18} & N & R^{23} \\
R^{21} & R^{26} & R^{25}
\end{array}$$
(V)

 R^{19} R^{18} R^{20} R^{22} R^{23} R^{21} R^{25} (VI)

that are androgen receptor modulators

and/or androgen receptor binding agents. Also disclosed are methods of making and using such compounds, including, but not limited to, using such compounds for treating various conditions.





According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

 $\frac{\text{Minimum documentation searched (classification system followed by classification symbols)}}{1PC~7~C07C~C07D~A61K~A61P}$

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

ategory °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	
	DATABASE WPI Section Ch, Week 200424 Derwent Publications Ltd., London, GB; Class B02, AN 2004-257164 XP002331455 -& WO 2004/016576 A1 (TAKEDA CHEM IND LTD) 26 February 2004 (2004-02-26) page 230; example 155	1-82	
(EP 1 122 242 A (YAMANOUCHI PHARMACEUTICAL CO. LTD) 8 August 2001 (2001-08-08) cited in the application page 39; compounds 1-33 page 1 claims 7,9	1-82	
		,	

Further documents are listed in the continuation of box C.	Patent family members are listed in annex.				
 Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed 	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "8" document member of the same patent family				
Date of the actual completion of the international search	Date of mailing of the international search report				
15 June 2005	0 5. 08. 2005				
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Seitner, I				





Category °	tion) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	12	
Category			claim No.
	Citation of Gooding, managed and, more appropriate for the following party and	neievalit to t	aam No.
х	US 4 097 578 A (PERRONNET ET AL) 27 June 1978 (1978-06-27) cited in the application columns 1-2	1-8	32
x	WO 03/011824 A (BRISTOL-MYERS SQUIBB COMPANY; SUN, CHONGQING; ROBL, JEFFREY, A; SALVAT) 13 February 2003 (2003-02-13) cited in the application example 1 claims 7-11	1-8	32
P,X	WO 2005/000795 A (SMITHKLINE BEECHAM CORPORATION; BLANC, JEAN-BAPTISTE, E; CADILLA, RODO) 6 January 2005 (2005-01-06) examples 113,119,120,135 claims 37-42	1-8	32
x	ANLEZARK G M ET AL: "BIOACTIVATION OF DINITROBENZAMIDE MUSTARDS BY AN E.COLI B NITROREDUCTASE" BIOCHEMICAL PHARMACOLOGY, PERGAMON, OXFORD, GB, vol. 50, no. 5, January 1995 (1995-01), pages 609-618, XP000645552 ISSN: 0006-2952 example 1; table 2		61,73, ,78,79
X .	PANTHANANICKAL, AUGUSTINE ET AL: "Structure-activity relationship of aniline mustards acting against B-16 melanoma in mice" JOURNAL OF MEDICINAL CHEMISTRY, 22(10), 1267-9 CODEN: JMCMAR; ISSN: 0022-2623, 1979, XP002331449 table I; compound 7	1,74	61,73, ,78,79
X	GRAVATT, G. LANCE ET AL: "DNA-Directed Alkylating Agents. 6. Synthesis and Antitumor Activity of DNA Minor Groove-Targeted Aniline Mustard Analogs of Pibenzimol (Hoechst 33258)" JOURNAL OF MEDICINAL CHEMISTRY, 37(25), 4338-45 CODEN: JMCMAR; ISSN: 0022-2623, 1994, XP002331450 abstract examples 14,19	1,	61
X	TURNBULL, KENNETH ET AL: "The reaction of 4-substituted aryl isocyanates with NaBH4/trifluoroacetic acid (TFA)" SYNTHESIS, (3), 391-392 CODEN: SYNTBF; ISSN: 0039-7881, 1999, XP008048153 scheme: compound 3e	1,	61
	-/		





		7 6 17 0320037 007 007			
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	Relevant to claim No.			
Category °	Citation of document, with indication, where appropriate, of the relevant passages	The evaluate or organization			
X	NICULESCU-DUVAZ D ET AL: "Self-immolative nitrogen mustard prodrugs for suicide gene therapy" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 41, no. 26, 17 December 1998 (1998-12-17), pages 5297-5309, XP002265049 ISSN: 0022-2623	1,61			
	compound 49 50				
X .	EP 0 711 768 A (MITSUI TOATSU CHEMICALS, INC; MITSUI CHEMICALS, INC) 15 May 1996 (1996-05-15) page 297, line 16 page 315, line 49 page 326, line 3 page 334, line 17 page 339, line 17	1,61			
X	PALMER, BRIAN D. ET AL: "Hypoxia-selective antitumor agents. 5. Synthesis of water-soluble nitroaniline mustards with selective cytotoxicity for hypoxic mammalian cells" JOURNAL OF MEDICINAL CHEMISTRY, 35(17), 3214-22 CODEN: JMCMAR; ISSN: 0022-2623, 1992, XP002331451 table 1; compounds 7-10 11-14 examples 2,9,10,13,14	1,61,73, 74,78,79			
Х	PALMER, B. D. ET AL: "Nitro analogs of chlorambucil as potential hypoxia-selective anti-tumor drugs" ANTI-CANCER DRUG DESIGN , 5(4), 337-49 CODEN: ACDDEA; ISSN: 0266-9536, 1990, XP008048139 table I; compound 3 6 8 examples 4,8,25	1,61			
X	PALMER, BRIAN D. ET AL: "Hypoxia-selective antitumor agents. 3. Relationships between structure and cytotoxicity against cultured tumor cells for substituted N,N-bis(2-chloroethyl)anilines" JOURNAL OF MEDICINAL CHEMISTRY, 33(1), 112-21 CODEN: JMCMAR; ISSN: 0022-2623, 1990, XP000609118 examples 5-7; table I	1,61,73, 74,78,79			





		PC1/032005/00/86/
C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
Olicyony	onador or coccana, mor and analytic, or are relevant passages	Nesevalit to Gain (40.
X	DATABASE CAPLUS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; PRASMICKIENE, G. ET AL: "Synthesis and study of the reactivity of p-[bis(2- chloropropyl)amino]phenylalkanoic acids" XP002331454 retrieved from STN Database accession no. 1969:430178 CAS RN: 23004-87-7 abstract & IZVESTIYA AKADEMII NAUK SSSR, SERIYA KHIMICHESKAYA, (3), 643-6 CODEN: IASKA6; ISSN: 0002-3353, 1969,	1,61
X	POPP, FRANK D.: "Synthesis of potential anticancer agents. X. Preparation and reactions of aldehydes related to benzaldehyde mustard" JOURNAL OF MEDICINAL CHEMISTRY, 7(2), 210-12 CODEN: JMCMAR; ISSN: 0022-2623, 1964, XP002331453 page 212, column 1 example IX	1,61,73, 74,78,79
X	STEINMAN, MARTIN ET AL: "1-Poly(fluoroalkyl)benzodiazepines" JOURNAL OF MEDICINAL CHEMISTRY, 16(12), 1354-60 CODEN: JMCMAR; ISSN: 0022-2623, 1973, XP002295070 example 12; table I example 17; table II	1,61
X	ABELA MEDICI, ANTHONY J. ET AL: "Cytotoxic compounds. Part 21. Chloro-, methoxy-, and methoxycarbonyl-derivatives of (bis-2-chloroethylamino)-phenols and anilines" JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1: ORGANIC AND BIO-ORGANIC CHEMISTRY (1972-1999), (20), 2258-63 CODEN: JCPRB4; ISSN: 0300-922X, 1977, XP008048335 example 10	1,61,73, 74,78,79
X	US 4 202 895 A (INABA, SHIGEHO ET AL) 13 May 1980 (1980-05-13) column 9, line 62 - line 63	1,61
Α	WO 02/16310 A (GTX, INC; DALTON, JAMES; MILLER, DUANE, D; YIN, DONGHUA; HE, YALI) 28 February 2002 (2002-02-28) claim 1 examples 1,2	1,61, 63-82
	-/	





	tion) DOCUMENTS CONSIDERED TO BE RELEVANT				
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.			
A	WO 98/22432 A (YAMANOUCHI PHARMACEUTICAL CO., LTD; TANIGUCHI, NOBUAKI; OKADA, MINORU;) 28 May 1998 (1998-05-28) abstract page 33 - page 48	1,61, 63-82			
÷					
	<i>*</i>				
	ş				
	•				
•					
		*			



Information on patent family members



International Application No PCT/US2005/007867

						PC1/052005/00/86/		
	tent document in search report		Publication date		Patent family member(s)		Publication date	
WO	2004016576	A1	26-02-2004	AU	2003254993	A1	03-03-2004	
				BR	0313405		12-07-2005	
				CA	2495383		26-02-2004	
				EP	1553074		13-07-2005	
				JP	2004091486		25-03-2004	
ΕP	1122242	Α	08-08-2001	ΑU	754529		21-11-2002	
				ΑU	5654499		10-04-2000	
				BR	9914018		03-07-2001	
				CA	2345146		30-03-2000	
				EP	1122242		08-08-2001	
			,	JP	3390744		31-03-2003	
	•		•	US	2004010037	A1	15-01-2004	
				US	6673799	B1	06-01-2004	
			•	CN	1129581	C	03-12-2003	
				WO	0017163	A1	30-03-2000	
	•			JP	2003137873		14-05-2003	
			•	PL	346795	A1	25-02-2002	
				RU	2221785		20-01-2004	
	4007579		27 06 1070	ED	220276		27 OF 1077	
US	4097578	Α	27-06-1978	FR	2329276		27-05-1977	
			•	AU	500542 1909576	D∠ .	24-05-1979	
			•	AU			04-05-1978	
				BE	847742		28-04-1977	
				BG	60533		28-07-1995	
				CA	1086751		30-09-1980	
				CH	599164		12-05-1978	
				DE	2649925		12-05-1977	
				DK	487476		30-04-1977	
				. ES	452746		01-10-1977	
				GB I E	1518444		19-07-1978	
					43875		17-06-1981	
				JP	1289956		14-11-1985	
	-		•	JP.	52057176		11-05-1977	
	•			JP	60011701		27-03-1985	
			•	LU	76085		31-05-1977	
				LU	88282		04-05-1994	
				MD	246		31-07-1995	
				NL	930079		16-09-1993	
				NL SE	7611576 430502	и ,в,	03-05-1977	
				SE	7610859		21-11-1983 30-04-1977	
				SU	596165		28-02-1978	
			 -					
WO	03011824	Α	13-02-2003	EP	1414795		06-05-2004	
	•			WO	03011824		13-02-2003	
				US	2003055094		20-03-2003	
				US	2004092559	A1	13-05-2004	
WO	2005000795	Α	06-01-2005	WO	2005000795	A2	06-01-2005	
EP	0711768	Α	15-05-1996	CA	2168016	A1	07-12-1995	
				DE	69525418		21-03-2002	
			•	DE	69525418		17-10-2002	
				EP	0711768		15-05-1996	
				ÜS	5852011		22-12-1998	
		•		ES	2172585		01-10-2002	
				WO	9532960		07-12-1995	
				MO	3332300	, V.T	0/-12-1333	





Information on patent family members

International Application No PCT/US2005/007867

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
EP 0711768	A		JP	3258531	B2	18-02-2002
			JР		Α	07-01-1997
			KR	172649	B1	01-02-1999
US 4202895	Α	13-05-1980	NONE			
WO 0216310	Α	28-02-2002	AU	8523001	Α	04-03-2002
			BR	0114801	Α	14-10-2003
			CA	2420279	A1	28-02-2002
			CN	1471508	Α	28-01-2004
			EP	1401801	A1	31-03-2004
			EP	1491524	A2	29-12-2004
.*		•	JP	2004518617		24-06-2004
		,	WO	0216310	A1 -	28-02-2002
			US		A1	25-07-2002
			US		A1	25-07-2002
•			US	2002173495		21-11-2002
			US	2003022868		30-01-2003
			US	2003162761	–	28-08-2003
			US	2003232792		18-12-2003
		•	US	2003225040	A1	04-12-2003
		• •	US		A1	22-01-2004
			US	2004260108		23-12-2004
			US	2005038110	A1	17-02-2005
WO 9822432	Α	28-05-1998	ΑU	4966497	Α	10-06-1998
			WO	9822432	A1	28-05-1998